Entering text into the input field will update the search result below

Aerie Pharma completes enrollment in mid-stage netarsudil study in Japan

Jul. 09, 2019 6:48 AM ETAerie Pharmaceuticals, Inc. (AERI) StockBy: Douglas W. House, SA News Editor
  • Several months ahead of schedule, Aerie Pharmaceuticals (NASDAQ:AERI) has completed the enrollment of 215 open-angle glaucoma/ocular hypertension patients in a Phase 2 clinical trial in Japan evaluating netarsudil ophthalmic solution 0.02% (branded as Rhopressa in the U.S.) in this population. Topline results should be available in Q4.
  • If successful, Phase 3 studies will follow.

Recommended For You

More Trending News

Related Stocks

SymbolLast Price% Chg
AERI--
Aerie Pharmaceuticals, Inc.